Trial Profile
A Phase II, Open-label Study to Assess the Efficacy, Safety, and Tolerability of AZD4635 in Combination with Durvalumab and in Combination with Cabazitaxel and Durvalumab in Patients Who Have Progressive Metastatic Castrate-Resistant Prostate Cancer (AARDVARC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Sep 2023
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Durvalumab (Primary) ; Imaradenant (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms AARDVARC
- Sponsors AstraZeneca; AstraZeneca AB
- 05 Sep 2022 Status changed from active, no longer recruiting to completed.
- 17 Aug 2022 This trial has been completed in Germany, according to European Clinical Trials Database record. (8 Aug 2022)
- 16 Dec 2021 This trial has been completed in France, according to European Clinical Trials Database record.